Geri
Genflow Biosciences plc (GENFF) Fiyatı
GENFF Hisse Senedi Fiyat Grafiği
GENFF Kazanmak
Genflow Biosciences plc
$0.03
0%
$0
Kapanışta: Jan 27, 16:00:00 GMT-5
$0.03
0%
$0
Sonrası Piyasa: Jan 27, 20:00:00 GMT-5
Earnings FAQ
GENFF'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Genflow Biosciences plc GENFF'ün son çeyrekteki geliri nasıl performans gösterdi?
Genflow Biosciences plc'in gelir tahmini nedir?
Genflow Biosciences plc'in kazanç kalite puanı nedir?
Genflow Biosciences plc kazançlarını ne zaman rapor eder?
Genflow Biosciences plc'in beklenen kazançları nelerdir?
Genflow Biosciences plc kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$0.0383
Açılış fiyatı
$0.0298
Günün Aralığı
$0.0298 - $0.0383
52 haftalık aralık
$0.01 - $0.0645
İşlem hacmi
110.0K
Ort.Hacim
13.6K
EPS (TTM)
-0.01
Dividend yield
--
Piyasa Değeri
$18.9M
Genflow Biosciences Plc nedir?
Genflow Biosciences Plc operates as a biotechnology company, which engages in the research and development of gene therapies to counteract the effects of aging and diseases associated with advanced age. The firm is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The firm's product pipeline includes GF-1002, GF-1003, GF-1004, GF-1005 and GF-1006. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-1004 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-1003 is a formulation of an adeno-associated viral vector-based gene therapy. The firm has operations in the United Kingdom and Belgium.
Özellikler
Ticaret Stratejileri
Kaynaklar
© 2025 Finture Development Limited. All rights reserved